ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "rheumatoid arthritis (RA) and tocilizumab"

  • Abstract Number: 465 • 2017 ACR/ARHP Annual Meeting

    Basement Membrane Remodeling in Rheumatoid Arthritis Associates with Disease Activity, Response to IL-6 Inhibitor Treatment and Radiographic Progression: Analysis of Two Phase III Clinical Trials

    Natasja Stæhr Gudman1, Pernille Juhl1, Christian S. Thudium2, Peter Junker3, Anne Sofie Siebuhr4, Inger Byrjalsen1, Morten Karsdal5 and Anne C. Bay-Jensen4, 1Nordic Bioscience, Herlev, Denmark, 2Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 3Department of Rheumatology C, Odense University Hospital, Odense, Denmark, 4Rheumatology, Nordic Bioscience, Herlev, Denmark, 5Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark

    Background/Purpose: Rheumatoid arthritis (RA) is associated with neovascularization of the synovial membrane and increased risk of cardiovascular co-morbidity. The extra cellular matrix below the endothelial…
  • Abstract Number: 2475 • 2017 ACR/ARHP Annual Meeting

    Clinical Remission in Subjects with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab As Monotherapy or in Combination with Methotrexate or Other Synthetic Dmards: A Real-World Clinical Trial

    Raimon Sanmartí1, Emilio Martín-Mola2, João E. Fonseca3, Douglas J. Veale4, Alejandro Escudero-Contreras5 and Carlos M Gonzalez6, 1Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, 2Hospital La Paz, Madrid, Spain, 3Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, Lisbon, Portugal, 4Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, 5Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 6Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

    Background/Purpose: the primary objective of this study was to assess the 24-week efficacy and safety of subcutaneous (SC) tocilizumab (TCZ) 162 mg weekly (qw) as…
  • Abstract Number: 527 • 2017 ACR/ARHP Annual Meeting

    Cardiovascular Safety of Tocilizumab Versus Abatacept in Patients with Rheumatoid Arthritis: A Multi-Database Study

    Seoyoung C. Kim1, Daniel H. Solomon1, James R. Rogers2, Sara Gale3, Micki Klearman3, Khaled Sarsour3 and Sebastian Schneeweiss2, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Genentech, South San Francisco, CA

    Background/Purpose: While tocilizumab (TCZ) may increase serum lipid levels, recent studies do not suggest an increased cardiovascular (CV) risk associated with TCZ use compared to…
  • Abstract Number: 2962 • 2017 ACR/ARHP Annual Meeting

    MRI Results Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial

    Charles Peterfy1, Joel Kremer2, William F C Rigby3, Nora Singer4, Christine Birchwood5, Darcy Gill5, William Reiss5, Jinglan Pei5 and Margaret Michalska5, 1Spire Sciences, Inc., Boca Raton, FL, 2Albany Medical College, Albany, NY, 3Geisel School of Medicine at Dartmouth, Lebanon, NH, 4Case Western Reserve University School of Medicine, Cleveland, OH, 5Genentech, Inc., South San Francisco, CA

    Background/Purpose: Although previous studies have established the efficacy of tocilizumab (TCZ) initiated as monotherapy (MONO) for the treatment of rheumatoid arthritis (RA),1,2 changes in active…
  • Abstract Number: 1399 • 2017 ACR/ARHP Annual Meeting

    Tissues Are Differently Modulated By Tocilizumab and Methotrexate; Assessment of Connective Tissue Metabolites in the Ambition Study

    Anne C. Bay-Jensen1, Anne Sofie Siebuhr1, Christian S. Thudium2 and Morten Asser Karsdal1, 1Rheumatology, Nordic Bioscience, Herlev, Denmark, 2Biomarkers and Research, Nordic Bioscience, Herlev, Denmark

    Background/Purpose: The response to any treatment in rheumatoid arthritis (RA) is assessed by symptomatic changes, such as swollen joint count and DAS28. However, such assessments…
  • Abstract Number: 1423 • 2017 ACR/ARHP Annual Meeting

    Patterns of Prednisone Use in US Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine Clinical Practice

    Dimitrios A. Pappas1, Carol J. Etzel2, Jennie Best3, Steve Zlotnick3, Taylor Blachley2, Gioia Persuitte2 and Joel Kremer4, 1Columbia University, New York, NY, 2Corrona, LLC, Southborough, MA, 3Genentech, Inc., South San Francisco, CA, 4Albany Medical College and The Center for Rheumatology, Albany, NY

    Background/Purpose: There are limited data regarding the impact of tocilizumab (TCZ) treatment on prednisone use in patients with rheumatoid arthritis (RA). The objective of this…
  • Abstract Number: 1426 • 2017 ACR/ARHP Annual Meeting

    Higher Levels of Interleukin-6 As Well As Soluble Interleukin-6 Receptor Leads to Worse Clinical and Radiographic Prognosis in Rheumatoid Arthritis Patients Treated with Tocilizumab

    Naoshi Nishina, Yuko Kaneko, Keiko Yoshimoto and Tsutomu Takeuchi, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: We have already reported that baseline levels of soluble interluekin-6 receptor (sIL-6R), target of tocilizumab, predicted response to tocilizumab treatment in rheumatoid arthritis (RA)…
  • Abstract Number: 1439 • 2017 ACR/ARHP Annual Meeting

    Factors Influencing the Prescription of Tocilizumab Alone or in Combination with Dmards in Rheumatoid Arthritis Patients in a Real Life Setting. Pooled Analysis of 2 Observational Studies

    Alain Saraux1, René-Marc Flipo2, Bernard Combe3, Jacques Tebib4, Christelle Baffie5, Isabelle Idier6 and Alain Cantagrel7, 1Rheumatology Department, Rheumatology Department, CHU de la Cavale Blanche, Brest, France, Brest Cedex, France, 2Rheumatology, Department of Rheumatology, CHU Teaching Hospital Lille, France., Lille, France, 3Rheumatology, Lapeyronie Hospital, Montpellier I university, Montpellier, France, 4Rheumatology, University Hospital, Hospices civils de Lyon, Lyon, France, 5Statistics, Altizem on behalf of Roche, Boulogne Billancourt, France, 6Medical department, Chugai Pharma France, Paris La Defense, France, 7Department of Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, Toulouse, France

    Background/Purpose: Tocilizumab (TCZ) as monotherapy (Mono) is nowadays a standard treatment in rheumatoid arthritis (RA) for patients in whom methotrexate (MTX) gives an inadequate response1.…
  • Abstract Number: 1467 • 2017 ACR/ARHP Annual Meeting

    Changes in the Immune Response of RA Patients Induced By 1 Year of Tocilizumab

    Cesar Diaz-Torné1, Paula Estrada2, Patricia Moya3, Maria A. Ortiz4, Diana de la Fuente5, Mireia Moreno6, Noemí Busquets7, Julio Ramírez8, Carme Moragues9, Sergi Ros5, Enrique Casado Burgos6, Vicente Torrente10, Elizabeth Garcia11, Manel Pujol12, Andrés Ponce13, Silvia Vidal4 and Juan José de Agustín14, 1Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, 2Rheumatology, Hospital Moisès Broggi-Hospital General de L´Hospitalet. Consorci Sanitari Integral, Barcelona, Spain, 3Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 4Institut de Recerca Sant Pau, Barcelona, Spain, 5Rheumatology, Hospital de Viladecans, Viladecans, Spain, 6Rheumatology, Parc Tauli Hospital Universitari, Sabadell, Spain, 7Rheumatology, Hospital General de Granollers, Granollers, Spain, 8Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, 9Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 10Hospital Moisès Broggi-Hospital General de L´Hospitalet. Consorci Sanitari Integral, L'Hospitalet de Llobregat, Spain, 11Rheumatology, Hospital de Mollet, Mollet, Spain, 12Hospital Mútua de Terrassa, Terrassa, Spain, 13Rheumatology. Internal Medicine, Hospital General de Granollers, Granollers, Spain, 14Rheumatology, Hospital Vall d´Hebrón, Barcelona, Spain

    Background/Purpose: Tocilizumab, a humanized anti-human IL-6 receptor antibody that blocks the signaling of IL-6/IL-6R complex, is an effective treatment in chronic inflammatory rheumatoid arthritis (RA).…
  • Abstract Number: 1476 • 2017 ACR/ARHP Annual Meeting

    Effect of Treat-to-Target Tocilizumab- and Methotrexate-Based Strategies on Health-Related Quality of Life in Newly Diagnosed Rheumatoid Arthritis Patients: Results of the U-Act-Early Trial

    Xavier M Teitsma1, Johannes WG Jacobs1, Paco MJ Welsing2, Attila Pethö-Schramm3, Michelle EA Borm4, Jacob M. van Laar5, Floris PJ Lafeber5 and Johannes W.J. Bijlsma2, 1Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3F. Hoffmann-La Roche, Basel, Switzerland, 4Beneluxlaan 2a, Roche Nederland BV, Woerden, Netherlands, 5Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Patient-reported outcomes are, in addition to other efficacy and safety related outcomes, important reflections of effectiveness and adverse effects of a therapy. The Outcomes…
  • Abstract Number: 1825 • 2017 ACR/ARHP Annual Meeting

    Comparative Analysis of Achievement of Individual Important Response Measured By DAS28dcrit in a Randomized Head-to-Head Trial of Tocilizumab Vs. Adalimumab in Active Rheumatoid Arthritis

    Michaela Koehm1, Michael Hofmann2, Rasmus Lüthje2, Matthew McIntosh3, Varghese Abraham3, Cem Gabay4, Arthur Kavanaugh5, Harald Burkhardt6 and Frank Behrens6, 1Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, 2Rheumatology, Chugai Pharma Europe Ltd., Frankfurt, Germany, 3Genentech, San Francisco, CA, 4SCQM, Geneva, Switzerland, Geneva, Switzerland, 5Medicine, University of California, San Diego, La Jolla, CA, 6Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany

    Background/Purpose: Fluctuations in disease activity due to short-term situational effects and measurement errors are important considerations for evaluation of individual clinically meaningful therapeutic response in…
  • Abstract Number: 1905 • 2017 ACR/ARHP Annual Meeting

    Sustained Response Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial

    Joel Kremer1, William F C Rigby2, Nora Singer3, Christine Birchwood4, Darcy Gill4, William Reiss4, Jinglan Pei4 and Margaret Michalska4, 1Albany Medical College, Albany, NY, 2Geisel School of Medicine at Dartmouth, Lebanon, NH, 3Case Western Reserve University School of Medicine, Cleveland, OH, 4Genentech, Inc., South San Francisco, CA

    Background/Purpose: Although methotrexate (MTX) is often administered in combination with biologics for the treatment of rheumatoid arthritis (RA), it may be discontinued due to intolerance…
  • Abstract Number: 2449 • 2017 ACR/ARHP Annual Meeting

    Comparative Effectiveness of Tocilizumab (TCZ) Monotherapy with Tumor Necrosis Factor Inhibitors (TNFi) in Combination with Varying Doses of Methotrexate (MTX) in Patients with Rheumatoid Arthritis

    Leslie R Harrold1, George W. Reed1, Jennie Best2, Steve Zlotnick2, Gioia Persuitte3 and Joel Kremer4, 1University of Massachusetts Medical School, Worcester, MA, 2Genentech, Inc., South San Francisco, CA, 3Corrona, LLC, Southborough, MA, 4Albany Medical College and The Center for Rheumatology, Albany, NY

    Background/Purpose: Clinical studies have shown that the efficacy of TCZ monotherapy (TCZ mono) is superior to that of TNFi monotherapy and comparable to that of…
  • Abstract Number: 2458 • 2017 ACR/ARHP Annual Meeting

    Tocilizumab Inhibits Progression of Erosive Joint Damage in Early Rheumatoid Arthritis More Effectively Than Step-up Methotrexate Therapy

    Xavier M Teitsma1, Johannes WG Jacobs1, Paco MJ Welsing2, Attila Pethö-Schramm3, Michelle EA Borm4, Jacob M. van Laar5, Floris PJ Lafeber5 and Johannes W.J. Bijlsma2, 1Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3F. Hoffmann-La Roche, Basel, Switzerland, 4Beneluxlaan 2a, Roche Nederland BV, Woerden, Netherlands, 5Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: In early rheumatoid arthritis (RA), starting therapy as soon as possible is important to reduce disease activity and preserve the joints. With application of…
  • Abstract Number: 2460 • 2017 ACR/ARHP Annual Meeting

    Patient-Reported Outcomes Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial

    Joel Kremer1, William F C Rigby2, Nora Singer3, Christine Birchwood4, Darcy Gill4, William Reiss4, Jennie Best4, Jinglan Pei4 and Margaret Michalska4, 1Albany Medical College, Albany, NY, 2Geisel School of Medicine at Dartmouth, Lebanon, NH, 3Case Western Reserve University School of Medicine, Cleveland, OH, 4Genentech, Inc., South San Francisco, CA

    Background/Purpose: Patients with rheumatoid arthritis (RA) often receive methotrexate (MTX) in combination with biologics; however, MTX may be discontinued due to intolerance or to reduce…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.